首页> 外文期刊>Oncology Research >miR-34b Targets HSF1 to Suppress Cell Survival in Acute Myeloid Leukemia
【24h】

miR-34b Targets HSF1 to Suppress Cell Survival in Acute Myeloid Leukemia

机译:miR-34b靶向HSF1抑制急性髓细胞白血病中的细胞存活

获取原文
获取原文并翻译 | 示例
       

摘要

Acute myeloid leukemia (AML) is the most lethal hematological malignancy, and the occurrence of chemoresistance prevents the achievement of complete remission following the standard therapy. MicroRNAs have been extensively investigated as critical regulators of hematopoiesis and leukemogenesis, and they represent a promising strategy for AML therapy. In this study, we identified miR-34b as a novel regulator in myeloid proliferation and apoptosis of leukemic cells. We found that miR-34b was developmentally upregulated in plasma and myeloid cells of healthy subjects, while it was significantly reduced in blood samples of patients with AML and AML cell lines. Moreover, the miR-34b mimicked transfection-mediated restoration of miR-34b inhibited cell viability and promoted cell apoptosis of HL-60 and OCI-AML3 cell lines. Using a miRNA predicting algorithm miRanda, we selected a potent target heat shock transcription factor 1 (HSF1) since that is a master regulator of the heat shock response and is associated with cancer aggressiveness and dissemination. In contrast to the level of miR-34b, HSF1 was highly expressed in blood samples of patients with AML and AML cell lines. The luciferase reporter assay revealed that miR-34b directly targeted the HSF1 gene. HSF1 silencing exhibited comparable inhibitory effects on AML cell proliferation and survival. The upregulated HSF1 elevated the activation of the Wnt-beta-catenin pathway. In conclusion, miR-34b suppressed AML cell proliferation and survival by targeting HSF1, in turn leading to the inactivation of Wnt beta-catenin pathway, which may highlight a new therapeutic approach for AML.
机译:急性髓细胞性白血病(AML)是最致命的血液系统恶性肿瘤,化学抗药性的发生阻止了标准疗法后完全缓解。 MicroRNA已被广泛研究为造血和白血病生成的关键调节剂,它们代表了AML治疗的一种有前途的策略。在这项研究中,我们确定了miR-34b是白血病细胞骨髓增殖和凋亡中的新型调节剂。我们发现,在健康受试者的血浆和髓样细胞中,miR-34b在发育上被上调,而在AML和AML细胞系患者的血液样本中,miR-34b明显降低。此外,miR-34b模仿了转染介导的miR-34b还原,抑制了细胞活力并促进了HL-60和OCI-AML3细胞系的细胞凋亡。使用miRNA预测算法miRanda,我们选择了有效的靶标热休克转录因子1(HSF1),因为它是热休克反应的主要调节因子,并且与癌症的侵袭性和传播有关。与miR-34b的水平相比,HSF1在AML和AML细胞系患者的血液样本中高表达。萤光素酶报告基因检测显示miR-34b直接靶向HSF1基因。 HSF1沉默表现出对AML细胞增殖和存活的类似抑制作用。上调的HSF1升高了Wnt-β-catenin途径的激活。总之,miR-34b通过靶向HSF1抑制AML细胞的增殖和存活,进而导致Wntβ-catenin途径失活,这可能是AML的一种新治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号